首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Hematopoietic stem cell transplantation for infantile osteopetrosis
【24h】

Hematopoietic stem cell transplantation for infantile osteopetrosis

机译:造血干细胞移植治疗婴儿骨质疏松症

获取原文
获取原文并翻译 | 示例
           

摘要

We report the international experience in outcomes after related and unrelated hematopoietic transplantation for infantile osteopetrosis in 193 patients. Thirty-four percent of transplants used grafts from HLA-matched siblings, 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donors. The median age at transplantation was 12 months. Busulfan and cyclophosphamide was the most common conditioning regimen. Long-term survival was higher after HLA-matched sibling compared to alternative donor transplantation. There were no differences in survival after HLA mismatched related, HLA-matched unrelated, or mismatched unrelated donor transplantation. The 5- and 10-year probabilities of survival were 62% and 62% after HLA-matched sibling and 42% and 39% after alternative donor transplantation (P=.01 and P=.002, respectively). Graft failure was the most common cause of death, accounting for 50% of deaths after HLA-matched sibling and 43% of deaths after alternative donor transplantation. The day-28 incidence of neutrophil recovery was 66% after HLA-matched sibling and 61% after alternative donor transplantation (P=.49). The median age of surviving patients is 7 years. Of evaluable surviving patients, 70% are visually impaired; 10% have impaired hearing and gross motor delay. Nevertheless, 65% reported performance scores of 90 or 100, and in 17%, a score of 80 at last contact. Most survivors >5 years are attending mainstream or specialized schools. Rates of veno-occlusive disease and interstitial pneumonitis were high at 20%. Though allogeneic transplantation results in long-term survival with acceptable social function, strategies to lower graft failure and hepatic and pulmonary toxicity are urgently needed.
机译:我们报告了193例婴儿和婴儿骨质疏松症相关和不相关的造血移植术后结果的国际经验。 34%的移植使用了来自HLA匹配的兄弟姐妹的移植物,13%的来自HLA匹配的亲戚,12%的HLA匹配的亲戚和41%的HLA匹配的不相关供体。移植时的中位年龄为12个月。白消安和环磷酰胺是最常见的调理方案。与替代供体移植相比,HLA匹配的同胞后的长期存活率更高。 HLA不匹配的相关,HLA匹配的不相关或不匹配的不相关供体移植后的生存率无差异。 HLA匹配的同胞后的5年和10年生存率分别为62%和62%,以及其他供体移植后分别为42%和39%(分别为P = .01和P = .002)。嫁接失败是最常见的死亡原因,占HLA匹配的同胞后死亡的50%,替代供体移植后死亡的43%。 HLA匹配的同胞后第28天中性粒细胞恢复的发生率为66%,而其他供体移植后为61%(P = .49)。存活患者的中位年龄为7岁。在可评估的存活患者中,有70%的视力障碍; 10%的人有听力障碍和明显的运动延迟。尽管如此,仍有65%的人表现得分为90或100,有17%的人最后一次接触得分为80。大多数5岁以上的幸存者都在主流学校或专业学校就读。静脉阻塞性疾病和间质性肺炎的发生率高达20%。尽管同种异体移植可实现具有可接受社会功能的长期存活,但迫切需要降低移植失败率以及肝和肺毒性的策略。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号